<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777749</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ0850</org_study_id>
    <nct_id>NCT02777749</nct_id>
  </id_info>
  <brief_title>Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty</brief_title>
  <official_title>Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the efficacy of adductor canal blocks versus
      periarticular bupivacaine injections for pain management in total knee arthroplasty. This
      randomized clinical trial will compare outcomes between adductor canal blocks, periarticular
      bupivacaine injections, and periarticular liposomal bupivacaine injections. Results from this
      study will help determine the most appropriate perioperative pain management strategy for
      patients undergoing a total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 600,000 total knee arthroplasties (TKAs) are performed each year in the United States,
      with expectations for greater than 4 million/year by the year 2030. Since the onset of TKAs
      in the 1960's, there have been developments that have improved both functionality and patient
      satisfaction. In the last decade, a focus has been made on multimodal pain management
      protocols, more rapid functional recovery, reduced length of hospital stay, and minimizing
      side effects of treatment while maintaining function and durability. The widespread use of
      regional anesthesia has led to improvements in pain control, more rapid functional recovery,
      and reduced length of stay. In recent years many surgeons have transitioned from femoral
      nerve blocks (proximal femoral nerve) to adductor canal blocks (distal femoral nerve) to
      maintain a sensory block for pain control, while minimizing any motor blockade that is
      typically seen in proximal femoral nerve blocks, which would hamper rehabilitation, and
      increase risk of falls. In addition to regional blocks, which are typically performed in the
      preoperative setting, some surgeons favor an intraoperative periarticular anesthetic
      injection (PAI), typically with bupivacaine or the long acting form liposomal bupivacaine,
      either in conjunction with an adductor canal block, or independently. In theory, PAI has the
      advantage of a comparable sensory nerve block as an adductor canal block, without the
      disadvantages and risks, which include prolonged quadriceps weakness, fall risk, and
      neurologic dysfunction.

      The purpose of this randomized control trial is to compare the efficacy of adductor canal
      blocks versus periarticular bupivacaine injections for pain management in total knee
      arthroplasty.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2016</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 19, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS Pain Scores</measure>
    <time_frame>Day 0 through Day 3</time_frame>
    <description>Post-operatively, visual analog scale (VAS) pain scores will be recorded two times/day from Post-Operative Day (POD) 0 through POD3. VAS Scores range from 0 to 10, with 0 being &quot;No Pain&quot; and 10 being the &quot;Worst Pain&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Activity Level</measure>
    <time_frame>Day 0 and Day 1</time_frame>
    <description>Daily steps taken will be recorded. The more steps taken daily the better. Minimum is 0 steps, maximum is unlimited.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Day 0 through Day 3</time_frame>
    <description>Total amount of opioid consumption post-operatively will be recorded. The less opioids consumed (mg) postoperatively the better. A morphine equivalence metric will be used for equianalgesic comparison. Minimum is 0 mg, maximum is unlimited.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Knee Flexion</measure>
    <time_frame>Postoperative day 21</time_frame>
    <description>Range of knee flexion for active motion will be recorded at 3 week follow-up for all groups. The greater range of motion the better, with a good outcome considered at least 115 degrees of motion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>Total length of hospital stay from time of surgery through time of discharge will be recorded. The shorter the length of stay (days) the better. Range 0 days to 5 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Adductor Canal Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periarticular SB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB + SB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection</description>
    <arm_group_label>ACB + SB</arm_group_label>
    <arm_group_label>Adductor Canal Block</arm_group_label>
    <arm_group_label>Periarticular SB</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients undergoing an unilateral primary total knee arthroplasty under the care of the
        two senior arthroplasty surgeons.

        Exclusion Criteria:

        - Allergy to bupivicaine or liposomal bupivicaine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Geller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA. 2012 Sep 26;308(12):1227-36.</citation>
    <PMID>23011713</PMID>
  </reference>
  <reference>
    <citation>Berend ME, Berend KR, Lombardi AV Jr. Advances in pain management: game changers in knee arthroplasty. Bone Joint J. 2014 Nov;96-B(11 Supple A):7-9. doi: 10.1302/0301-620X.96B11.34514. Review.</citation>
    <PMID>25381400</PMID>
  </reference>
  <reference>
    <citation>Paul JE, Arya A, Hurlburt L, Cheng J, Thabane L, Tidy A, Murthy Y. Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials. Anesthesiology. 2010 Nov;113(5):1144-62. doi: 10.1097/ALN.0b013e3181f4b18. Review.</citation>
    <PMID>20966667</PMID>
  </reference>
  <reference>
    <citation>Grevstad U, Mathiesen O, Valentiner LS, Jaeger P, Hilsted KL, Dahl JB. Effect of adductor canal block versus femoral nerve block on quadriceps strength, mobilization, and pain after total knee arthroplasty: a randomized, blinded study. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):3-10. doi: 10.1097/AAP.0000000000000169.</citation>
    <PMID>25376972</PMID>
  </reference>
  <reference>
    <citation>Wang C, Cai XZ, Yan SG. Comparison of Periarticular Multimodal Drug Injection and Femoral Nerve Block for Postoperative Pain Management in Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2015 Jul;30(7):1281-6. doi: 10.1016/j.arth.2015.02.005. Epub 2015 Feb 20. Review.</citation>
    <PMID>25735501</PMID>
  </reference>
  <reference>
    <citation>Schroer WC, Diesfeld PG, LeMarr AR, Morton DJ, Reedy ME. Does Extended-Release Liposomal Bupivacaine Better Control Pain Than Bupivacaine After Total Knee Arthroplasty (TKA)? A Prospective, Randomized Clinical Trial. J Arthroplasty. 2015 Sep;30(9 Suppl):64-7. doi: 10.1016/j.arth.2015.01.059. Epub 2015 Jun 3.</citation>
    <PMID>26117072</PMID>
  </reference>
  <reference>
    <citation>Berry J. Audience response-practice norm/trends. 22nd Annual Meeting of the American Association of Hip and Knee Surgeons. American Association of Hip and Knee Surgeons. November 2012.</citation>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>March 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2019</results_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Jeffrey Geller</investigator_full_name>
    <investigator_title>Associate Professor of Orthopedic Surgery at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02777749/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adductor Canal Block</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>Periarticular SB</title>
          <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="P3">
          <title>ACB + SB</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adductor Canal Block</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="B2">
          <title>Periarticular SB</title>
          <description>20 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>ACB + SB</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
20 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="10"/>
                    <measurement group_id="B2" value="73" spread="10"/>
                    <measurement group_id="B3" value="71" spread="10"/>
                    <measurement group_id="B4" value="71" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="51"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in VAS Pain Scores</title>
        <description>Post-operatively, visual analog scale (VAS) pain scores will be recorded two times/day from Post-Operative Day (POD) 0 through POD3. VAS Scores range from 0 to 10, with 0 being &quot;No Pain&quot; and 10 being the &quot;Worst Pain&quot;</description>
        <time_frame>Day 0 through Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adductor Canal Block</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Periarticular SB</title>
            <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>ACB + SB</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VAS Pain Scores</title>
          <description>Post-operatively, visual analog scale (VAS) pain scores will be recorded two times/day from Post-Operative Day (POD) 0 through POD3. VAS Scores range from 0 to 10, with 0 being &quot;No Pain&quot; and 10 being the &quot;Worst Pain&quot;</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.9"/>
                    <measurement group_id="O2" value="3.0" spread="3.0"/>
                    <measurement group_id="O3" value="2.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.3"/>
                    <measurement group_id="O2" value="3.8" spread="2.4"/>
                    <measurement group_id="O3" value="3.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.5"/>
                    <measurement group_id="O2" value="3.8" spread="2.4"/>
                    <measurement group_id="O3" value="3.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.1"/>
                    <measurement group_id="O2" value="3.0" spread="2.8"/>
                    <measurement group_id="O3" value="2.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Activity Level</title>
        <description>Daily steps taken will be recorded. The more steps taken daily the better. Minimum is 0 steps, maximum is unlimited.</description>
        <time_frame>Day 0 and Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adductor Canal Block</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Periarticular SB</title>
            <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>ACB + SB</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Activity Level</title>
          <description>Daily steps taken will be recorded. The more steps taken daily the better. Minimum is 0 steps, maximum is unlimited.</description>
          <units>steps</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="33"/>
                    <measurement group_id="O2" value="68" spread="63"/>
                    <measurement group_id="O3" value="65" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="117"/>
                    <measurement group_id="O2" value="120" spread="117"/>
                    <measurement group_id="O3" value="139" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>Total amount of opioid consumption post-operatively will be recorded. The less opioids consumed (mg) postoperatively the better. A morphine equivalence metric will be used for equianalgesic comparison. Minimum is 0 mg, maximum is unlimited.</description>
        <time_frame>Day 0 through Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adductor Canal Block</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Periarticular SB</title>
            <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>ACB + SB</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Total amount of opioid consumption post-operatively will be recorded. The less opioids consumed (mg) postoperatively the better. A morphine equivalence metric will be used for equianalgesic comparison. Minimum is 0 mg, maximum is unlimited.</description>
          <units>morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Combined (POD0 through POD3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" spread="74"/>
                    <measurement group_id="O2" value="100" spread="62"/>
                    <measurement group_id="O3" value="98" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="15"/>
                    <measurement group_id="O2" value="31" spread="18"/>
                    <measurement group_id="O3" value="35" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="25"/>
                    <measurement group_id="O2" value="42" spread="31"/>
                    <measurement group_id="O3" value="40" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="29"/>
                    <measurement group_id="O2" value="20" spread="22"/>
                    <measurement group_id="O3" value="18" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="23"/>
                    <measurement group_id="O2" value="5.5" spread="16"/>
                    <measurement group_id="O3" value="4.3" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Range of Knee Flexion</title>
        <description>Range of knee flexion for active motion will be recorded at 3 week follow-up for all groups. The greater range of motion the better, with a good outcome considered at least 115 degrees of motion.</description>
        <time_frame>Postoperative day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adductor Canal Block</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Periarticular SB</title>
            <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>ACB + SB</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Range of Knee Flexion</title>
          <description>Range of knee flexion for active motion will be recorded at 3 week follow-up for all groups. The greater range of motion the better, with a good outcome considered at least 115 degrees of motion.</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="15"/>
                    <measurement group_id="O2" value="104" spread="12"/>
                    <measurement group_id="O3" value="101" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>Total length of hospital stay from time of surgery through time of discharge will be recorded. The shorter the length of stay (days) the better. Range 0 days to 5 days.</description>
        <time_frame>Up to Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adductor Canal Block</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Periarticular SB</title>
            <description>50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>ACB + SB</title>
            <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or50 cc's short-acting bupivacaine (SB), intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>Total length of hospital stay from time of surgery through time of discharge will be recorded. The shorter the length of stay (days) the better. Range 0 days to 5 days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.2"/>
                    <measurement group_id="O3" value="2.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>postoperative day 0 through post-operative day 21.</time_frame>
      <desc>No serious adverse events, including mortality. This was a healthy cohort of patients undergoing elective surgery for total knee replacement. There were no expected adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adductor Canal Block</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
Adductor Canal Block (ACB)
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="E2">
          <title>Periarticular SB</title>
          <description>50 cc’s of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
        <group group_id="E3">
          <title>ACB + SB</title>
          <description>15 cc’s of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
50 cc’s of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
Bupivacaine: 15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Matthew Grosso</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>2123058193</phone>
      <email>mgrosso13@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

